Contact PD/PI: Murphy, Timothy F The Buffalo Translational Consortium (BTC), which includes the University at Buffalo (UB) health sciences schools, the major healthcare institutions in our region, four key research institutes and five influential community partners, have embarked on a comprehensive strategic plan to build a strong foundation for clinical and translational research in response to our community needs. Buffalo is the second most populous city in New York State and has a rich cultural history. The proportion of underrepresented minorities in Buffalo in 2018 (50%) parallels that projected for the US in 2050, making Buffalo a microcosm of what the US will look like in 30 years. A similar proportion of our population experiences health disparities. The vision for our CTSA hub is to perform innovative research across the translational spectrum to improve the health of our community and the nation. We will develop, test and share novel approaches to engage difficult-to-engage populations and reduce health disparities in our community, which represents a ?population of the future?. Guided by our vision, the CTSA has catalyzed a transformation of our environment since our CTSA was first funded in August 2015 with remarkable growth in clinical and translational research. Further, in just the past year, the UB medical school has moved into a spectacular new building and our clinical partner, Kaleida Health, the largest healthcare system in the region, opened the new Oishei Children?s Hospital, both on the Buffalo Niagara Medical Campus and connected to the Clinical and Translational Research Center devoted entirely to clinical and translational research that opened in 2012. This rapid and continuing trajectory of growth in healthcare and research in the region has resulted in a new 21st century Academic Health Center with healthcare, medical education and clinical and translational research on one campus in the heart of Buffalo, creating a foundation to enhance the impact of our CTSA even further. While launching our CTSA, we have prioritized participation in the national consortium through hosting and testing Innovation Labs as a team science tool, working with multiple hubs on initiatives to solve translational research barriers and sharing tools that we have developed with the CTSA consortium, including novel health informatics tools. Our CTSA has five ambitious but achievable aims, including: 1) Accelerate innovative translational research with teams that engage communities, regional stakeholders and the national consortium; 2) Train an excellent, diverse workforce to advance translation of discoveries; 3) Enhance inclusion of special populations across the lifespan and difficult-to-engage populations; 4) Streamline clinical research processes focusing on quality and efficiency with emphasis on multisite studies; 5) Develop, test and share biomedical informatics tools to integrate data from multiple sources to speed translation. Guided by our vision to perform research to improve the health of our community and the nation, we will continue our momentum to expand translational research, train our diverse workforce, streamline processes, engage our community, and actively contribute to the national consortium. Page 243 Project Summary/Abstract Contact PD/PI: Murphy, Timothy F The University at Buffalo Clinical and Translational Science Institute (CTSI) is the coordinating center of the Buffalo Translational Consortium, which includes the region's premier research, educational and clinical institutions with influential community partners. The vision of the CTSI is to perform innovative clinical and translational research to reduce health disparities and improve the health of our community and the nation. We engage our community as research partners to create a shared environment to bring discoveries in the laboratory, clinic and community to benefit individual and public health. Page 244

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
2UL1TR001412-05A1
Application #
10053435
Study Section
Special Emphasis Panel (ZTR1)
Program Officer
Rosemond, Erica
Project Start
2015-08-12
Project End
2024-12-31
Budget Start
2020-02-10
Budget End
2020-12-31
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
State University of New York at Buffalo
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
038633251
City
Amherst
State
NY
Country
United States
Zip Code
14228
Schweser, Ferdinand; Preda, Marilena; Zivadinov, Robert (2018) Susceptibility Weighted MRI in Rodents at 9.4 T. Methods Mol Biol 1718:205-234
Belov, P; Jakimovski, D; Krawiecki, J et al. (2018) Lower Arterial Cross-Sectional Area of Carotid and Vertebral Arteries and Higher Frequency of Secondary Neck Vessels Are Associated with Multiple Sclerosis. AJNR Am J Neuroradiol 39:123-130
Zivadinov, Robert; Polak, Paul; Schweser, Ferdinand et al. (2018) Multimodal Imaging of Retired Professional Contact Sport Athletes Does Not Provide Evidence of Structural and Functional Brain Damage. J Head Trauma Rehabil 33:E24-E32
Pasquariello, Kyle Z; Han, Marina; Unal, Cagla et al. (2018) Adrenergic manipulation inhibits pavlovian conditioned approach behaviors. Behav Brain Res 339:278-285
Bergsland, Niels; Schweser, Ferdinand; Dwyer, Michael G et al. (2018) Thalamic white matter in multiple sclerosis: A combined diffusion-tensor imaging and quantitative susceptibility mapping study. Hum Brain Mapp 39:4007-4017
Johnson, Blair D; O'Leary, Morgan C; McBryde, Muhamed et al. (2018) Face cooling exposes cardiac parasympathetic and sympathetic dysfunction in recently concussed college athletes. Physiol Rep 6:e13694
Ihnatovych, Ivanna; Lew, Alexandra; Lazar, Evelyn et al. (2018) Timing of Wnt Inhibition Modulates Directed Differentiation of Medial Ganglionic Eminence Progenitors from Human Pluripotent Stem Cells. Stem Cells Int 2018:3983090
Talal, Andrew H; Dumas, Emily O; Bauer, Barbara et al. (2018) Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage. J Infect Dis 217:474-482
Schweser, Ferdinand; Zivadinov, Robert (2018) Quantitative susceptibility mapping (QSM) with an extended physical model for MRI frequency contrast in the brain: a proof-of-concept of quantitative susceptibility and residual (QUASAR) mapping. NMR Biomed 31:e3999
Zhu, Xu; Shen, Xiaomeng; Qu, Jun et al. (2018) Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells. Front Pharmacol 9:84

Showing the most recent 10 out of 238 publications